SCHEMBL9933216

SCHEMBL9933216

CC(C)(C)OC(=O)N1CCN(Cc2ccccc2F)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.72
KDM4E B2RXH2 6/20 0.72
POLB P06746 1/20 0.72
LMNA P02545 2/20 0.59
HTT P42858 1/20 0.59
KDM1A O60341 1/20 0.57
KDM1B Q8NB78 1/20 0.57
GPR119 Q8TDV5 1/20 0.56
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
MAPK1 P28482 1/20 0.53
CHRM2 P08172 1/20 0.53
CHRM4 P08173 1/20 0.53
CHRM1 P11229 1/20 0.53
CHRM3 P20309 1/20 0.53
ATM Q13315 1/20 0.51
MGLL Q99685 1/20 0.51
MAPT P10636 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
VEGFA P15692 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5815688 0.87 KDM4E (0.55) ALDH1A1KDM4EPOLBLMNAHTT
SCHEMBL1770721 0.86 VEGFA (0.69) ALDH1A1KDM4EPOLBLMNAHTT
SCHEMBL11900867 0.85 MPO (0.59) ALDH1A1KDM4EPOLBKDM1AGPR119
SCHEMBL2843836 0.85 ALDH1A1 (0.69) ALDH1A1KDM4EPOLBGPR119CHRM2
SCHEMBL28864301 0.85 ALDH1A1 (0.61) ALDH1A1KDM4EPOLBLMNAHTT
SCHEMBL4680824 0.84 KDM4E (0.57) ALDH1A1KDM4EPOLBKDM1AKDM1B
SCHEMBL376336 0.84 ALDH1A1 (0.60) ALDH1A1KDM4EPOLBLMNAKDM1A
SCHEMBL17276773 0.84 ALDH1A1 (0.72) ALDH1A1KDM4EPOLBLMNAHTT
SCHEMBL23434788 0.84 VEGFA (0.53) ALDH1A1KDM4EPOLBKDM1AKDM1B
SCHEMBL17109170 0.84 ALDH1A1 (0.58) ALDH1A1KDM4EPOLBGPR119KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ALDH1A1 534/4885KDM4E 3804/4885POLB 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.